BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 2004;100:2281-91. [PMID: 15160330 DOI: 10.1002/cncr.20270] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Tsai YT, Ko CA, Chen HC, Hsu CM, Lai CH, Lee YC, Tsai MS, Chang GH, Huang EI, Fang KH. Prognostic Value of CRP-Albumin-Lymphocyte (CALLY) Index in Patients Undergoing Surgery for Oral Cavity Cancer. J Cancer 2022;13:3000-12. [PMID: 36046647 DOI: 10.7150/jca.74930] [Reference Citation Analysis]
2 Li Z, Wang J, Chen C, He Q, Xu X, Da Z, Wang B, Wang M, Gao X, Zhang G, Gao Q, Si X, Luo Y, Ma X, Xu B. Intratumoral IL-28B Gene Delivery Elicits Antitumor Effects by Remodeling of the Tumor Microenvironment in H22-Bearing Mice. Journal of Immunology Research 2022;2022:1-13. [DOI: 10.1155/2022/1345971] [Reference Citation Analysis]
3 Wang Y, Kuo L, Weng H, Hsu C, Tsai M, Chang G, Lee Y, Huang EI, Tsai Y. Systemic Immun e–Inflammation Index as a Predictor for Head and Neck Cancer Prognosis: A Meta-Analysis. Front Oncol 2022;12:899518. [DOI: 10.3389/fonc.2022.899518] [Reference Citation Analysis]
4 Hwang M, Canzoniero JV, Rosner S, Zhang G, White JR, Belcaid Z, Cherry C, Balan A, Pereira G, Curry A, Niknafs N, Zhang J, Smith KN, Sivapalan L, Chaft JE, Reuss JE, Marrone K, Murray JC, Li QK, Lam V, Levy BP, Hann C, Velculescu VE, Brahmer JR, Forde PM, Seiwert T, Anagnostou V. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J Immunother Cancer 2022;10:e004688. [PMID: 35688557 DOI: 10.1136/jitc-2022-004688] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sakaguchi M, Maebayashi T, Aizawa T, Ishibashi N, Okada M. Association between unintentional splenic radiation and lymphopenia and high neutrophil/lymphocyte ratio after radiotherapy in patients with esophageal cancer. Transl Cancer Res 2021;10:5076-84. [PMID: 35116359 DOI: 10.21037/tcr-21-1765] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Rajwa P, Huebner NA, Hostermann DI, Grossmann NC, Schuettfort VM, Korn S, Quhal F, König F, Mostafaei H, Laukhtina E, Mori K, Motlagh RS, Yanagisawa T, Aydh A, Bryniarski P, Pradere B, Paradysz A, Baltzer PA, Grubmüller B, Shariat SF. Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy. J Pers Med 2021;11:1231. [PMID: 34834583 DOI: 10.3390/jpm11111231] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Cilibrasi C, Papanastasopoulos P, Samuels M, Giamas G. Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies. Int J Mol Sci 2021;22:12015. [PMID: 34769447 DOI: 10.3390/ijms222112015] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Iorio GC, Spieler BO, Ricardi U, Dal Pra A. The Impact of Pelvic Nodal Radiotherapy on Hematologic Toxicity: A Systematic Review with Focus on Leukopenia, Lymphopenia and Future Perspectives in Prostate Cancer Treatment. Crit Rev Oncol Hematol 2021;168:103497. [PMID: 34666186 DOI: 10.1016/j.critrevonc.2021.103497] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Wei B, Yu M, Yao J, Jiang M, An J, Yang J, Lin J, Zhao Y, Zhu Y. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma. Front Immunol 2021;12:657951. [PMID: 34531849 DOI: 10.3389/fimmu.2021.657951] [Reference Citation Analysis]
10 Rajwa P, Schuettfort VM, D'Andrea D, Quhal F, Mori K, Katayama S, Laukhtina E, Pradere B, Motlagh RS, Mostafaei H, Grossmann NC, Huebner N, Aulitzky A, Mun DH, Briganti A, Karakiewicz PI, Fajkovic H, Shariat SF. Impact of systemic Immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. Urol Oncol 2021:S1078-1439(21)00208-8. [PMID: 34116934 DOI: 10.1016/j.urolonc.2021.05.002] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
11 Rajwa P, Schuettfort VM, Quhal F, Mori K, Katayama S, Laukhtina E, Pradere B, Motlagh RS, Mostafaei H, Grossmann NC, Aulitzky A, Paradysz A, Karakiewicz PI, Fajkovic H, Zimmermann K, Heidenreich A, Gontero P, Shariat SF. Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy. World J Urol 2021. [PMID: 33997919 DOI: 10.1007/s00345-021-03715-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Ko CA, Fang KH, Hsu CM, Lee YC, Chang GH, Huang EI, Tsai MS, Tsai YT. The preoperative C-reactive protein-lymphocyte ratio and the prognosis of oral cavity squamous cell carcinoma. Head Neck 2021;43:2740-54. [PMID: 33991004 DOI: 10.1002/hed.26738] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
13 Fang KH, Chang SW, Lee YC, Huang EI, Lai CH, Chang GH, Tsai MS, Hsu CM, Tsai YT. Preoperative prognostic nutritional index predicts prognosis of patients with oral cavity cancer. Oral Dis 2021. [PMID: 33690959 DOI: 10.1111/odi.13840] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Tubin S, Khan MK, Gupta S, Jeremic B. Biology of NSCLC: Interplay between Cancer Cells, Radiation and Tumor Immune Microenvironment. Cancers (Basel) 2021;13:775. [PMID: 33673332 DOI: 10.3390/cancers13040775] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Liu Y, Liu X, Lin C, Jia X, Zhu H, Song J, Zhang Y. Noncoding RNAs regulate alternative splicing in Cancer. J Exp Clin Cancer Res 2021;40:11. [PMID: 33407694 DOI: 10.1186/s13046-020-01798-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
16 Xu P, Sun Y, Song Y, Jiao J, Shen B, Li W, Jiang C, Li Y, Zhang X, Yu J, Fu L, Guo X. ATM kinase regulates tumor immunoreactions in lymphocyte-predominant breast cancer through modulation of NKG2D ligand and TNF cytokines on tumor cells. Med Mol Morphol 2020;53:210-20. [PMID: 32067111 DOI: 10.1007/s00795-020-00247-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Zhao J, Huang W, Wu Y, Luo Y, Wu B, Cheng J, Chen J, Liu D, Li C. Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: a systematic review and meta-analysis. Cancer Cell Int 2020;20:15. [PMID: 31938023 DOI: 10.1186/s12935-020-1094-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
18 van Rossum PSN, Deng W, Routman DM, Liu AY, Xu C, Shiraishi Y, Peters M, Merrell KW, Hallemeier CL, Mohan R, Lin SH. Prediction of Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Development and Validation of a Pretreatment Nomogram. Pract Radiat Oncol 2020;10:e16-26. [PMID: 31369887 DOI: 10.1016/j.prro.2019.07.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
19 Mortezaee K, Najafi M, Farhood B, Ahmadi A, Potes Y, Shabeeb D, Musa AE. Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review. Life Sciences 2019;228:228-41. [DOI: 10.1016/j.lfs.2019.05.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 62] [Article Influence: 16.3] [Reference Citation Analysis]
20 Guo C, Wang L, Zhao Y, Jiang B, Luo J, Shi D. BOS-93, a novel bromophenol derivative, induces apoptosis and autophagy in human A549 lung cancer cells via PI3K/Akt/mTOR and MAPK signaling pathway. Exp Ther Med 2019;17:3848-58. [PMID: 30988770 DOI: 10.3892/etm.2019.7402] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
21 Lee YJ, Chung YS, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT. Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced-stage ovarian cancer. Cancer Med 2019;8:564-71. [PMID: 30652425 DOI: 10.1002/cam4.1956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
22 Cui J, Chen S, Bo Q, Wang S, Zhang N, Yu M, Wang W, Han J, Zhu Y, Shi B. Preoperative prognostic nutritional index and nomogram predicting recurrence-free survival in patients with primary non-muscle-invasive bladder cancer without carcinoma in situ. Onco Targets Ther 2017;10:5541-50. [PMID: 29200869 DOI: 10.2147/OTT.S146990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
23 Rajwa P, Życzkowski M, Paradysz A, Slabon-Turska M, Suliga K, Bujak K, Bryniarski P. Novel hematological biomarkers predict survival in renal cell carcinoma patients treated with nephrectomy. Arch Med Sci 2020;16:1062-71. [PMID: 32863995 DOI: 10.5114/aoms.2017.70250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
24 Wang M, Zhang C, Song Y, Wang Z, Wang Y, Luo F, Xu Y, Zhao Y, Wu Z, Xu Y. Mechanism of immune evasion in breast cancer. Onco Targets Ther 2017;10:1561-73. [PMID: 28352189 DOI: 10.2147/OTT.S126424] [Cited by in Crossref: 36] [Cited by in F6Publishing: 48] [Article Influence: 7.2] [Reference Citation Analysis]
25 Djouder N. Adaptive survival mechanism to glucose restrictions. Oncoscience 2016;3:302-3. [PMID: 28105448 DOI: 10.18632/oncoscience.332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
26 Lissoni P. Therapy implications of the role of interleukin-2 in cancer. Expert Review of Clinical Immunology 2017;13:491-8. [DOI: 10.1080/1744666x.2017.1245146] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
27 Mahasa KJ, Ouifki R, Eladdadi A, Pillis L. Mathematical model of tumor-immune surveillance. J Theor Biol 2016;404:312-30. [PMID: 27317864 DOI: 10.1016/j.jtbi.2016.06.012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
28 Cai C, Zhang J, Li M, Wu Z, Song KH, Zhan TW, Wang L, Sun Y. Interleukin 10-expressing B cells inhibit tumor-infiltrating T cell function and correlate with T cell Tim-3 expression in renal cell carcinoma. Tumor Biol 2016;37:8209-18. [DOI: 10.1007/s13277-015-4687-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
29 Joseph N, Dovedi SJ, Thompson C, Lyons J, Kennedy J, Elliott T, West CM, Choudhury A. Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer. Ann Oncol 2016;27:294-9. [PMID: 26578732 DOI: 10.1093/annonc/mdv546] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
30 Xu Y, Deng Q, He B, Pan Y, Li R, Gao T, Sun H, Song G, Wang S, Cho WC. The diplotype Fas −1377A/−670G as a genetic marker to predict a lower risk of breast cancer in Chinese women. Tumor Biol 2014;35:9147-61. [DOI: 10.1007/s13277-014-2175-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
31 Zhu J, Lu L, Cheng X, Xie R, Chen Z, Li Y, Lin G, Liu J, Yang Y. Association between CD95L polymorphism and cervical cancer risk: evidence from a meta-analysis. Tumour Biol 2014;35:5137-42. [PMID: 24619598 DOI: 10.1007/s13277-014-1652-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
32 Xu Y, He B, Li R, Pan Y, Gao T, Deng Q, Sun H, Song G, Wang S. Association of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies. PLoS One 2014;9:e90090. [PMID: 24598538 DOI: 10.1371/journal.pone.0090090] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
33 Bhatia A, Kumar Y. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. Expert Rev Clin Immunol 2014;10:41-62. [PMID: 24325346 DOI: 10.1586/1744666X.2014.865519] [Cited by in Crossref: 64] [Cited by in F6Publishing: 71] [Article Influence: 7.1] [Reference Citation Analysis]
34 Dalan AB, Timirci-kahraman O, Turan S, Kafadar AM, Yaylim I, Ergen A, Gormus U, Gulec-yilmaz S, Kaspar C, Isbir T. Association between FAS and FASL Genetic Variants and Risk of Primary Brain Tumor. International Journal of Neuroscience 2013;124:443-9. [DOI: 10.3109/00207454.2013.850083] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
35 DU Y, Hu L, Pan Y. Lack of association between the FAS/FASL polymorphisms and cervical cancer risk: A meta-analysis. Biomed Rep 2013;1:269-74. [PMID: 24648934 DOI: 10.3892/br.2013.56] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
36 Kelly MN, Zheng M, Ruan S, Kolls J, D'Souza A, Shellito JE. Memory CD4+ T cells are required for optimal NK cell effector functions against the opportunistic fungal pathogen Pneumocystis murina. J Immunol 2013;190:285-95. [PMID: 23203926 DOI: 10.4049/jimmunol.1200861] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
37 Taliouri E, Vrekoussis T, Vergetaki A, Agorastos T, Makrigiannakis A. Corticotropin-releasing hormone (CRH) is expressed in the human cervical carcinoma cells (HeLa) and upregulates the expression of Fas ligand. Tumor Biol 2013;34:125-30. [DOI: 10.1007/s13277-012-0519-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
38 Chiu HY, Sun GH, Chen SY, Wang HH, Ho MY, Chu CY, Wu WL, Jhou RS, Tsai YL, Huang RT, Sun KH, Tang SJ. Pre-existing Fas ligand (FasL) in cancer cells elicits tumor-specific protective immunity, but delayed induction of FasL expression after inoculation facilitates tumor formation. Mol Carcinog 2013;52:705-14. [PMID: 22488710 DOI: 10.1002/mc.21909] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
39 Pellegatta S, Cuppini L, Finocchiaro G. Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas. Expert Rev Anticancer Ther 2011;11:1759-74. [PMID: 22050025 DOI: 10.1586/era.11.102] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
40 Sun H, Liu Y, Bu D, Liu X, Norris JS, Xiao S. Efficient growth suppression and apoptosis in human laryngeal carcinoma cell line HEP-2 induced by an adeno-associated virus expressing human FAS ligand. Head Neck 2012;34:1628-33. [PMID: 22267220 DOI: 10.1002/hed.21985] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
41 Wang W, Zheng Z, Yu W, Lin H, Cui B, Cao F. Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett 2012;3:625-8. [PMID: 22740964 DOI: 10.3892/ol.2011.541] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
42 Zheng J, Fu R, Li J, Wang X. CpG oligonucleotides suppress HepG2 cells-induced Jurkat cell apoptosis via the Fas-FasL-mediated pathway. J Exp Clin Cancer Res 2011;30:48. [PMID: 21535900 DOI: 10.1186/1756-9966-30-48] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
43 Chen YX, Allars M, Maiti K, Angeli GL, Abou-Seif C, Smith R, Nicholson RC. Factors affecting cytotrophoblast cell viability and differentiation: Evidence of a link between syncytialisation and apoptosis. Int J Biochem Cell Biol 2011;43:821-8. [PMID: 21352948 DOI: 10.1016/j.biocel.2011.02.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
44 Ho MY, Tang SJ, Ng WV, Yang W, Leu SJ, Lin YC, Feng CK, Sung JS, Sun KH. Nucleotide-binding domain of phosphoglycerate kinase 1 reduces tumor growth by suppressing COX-2 expression. Cancer Sci. 2010;101:2411-2416. [PMID: 20731664 DOI: 10.1111/j.1349-7006.2010.01691.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
45 Li C, Li M, Shu X, Liu Y, Wu W. Antitumor effects of recombinant human Interleukin-6 on mouse bladder carcinoma through Fas-mediated apoptosis. Cancer Chemother Pharmacol 2010;66:981-6. [DOI: 10.1007/s00280-010-1336-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
46 Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Sawaya R. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res. 2010;16:461-473. [PMID: 20068105 DOI: 10.1158/1078-0432.ccr-09-1983] [Cited by in Crossref: 174] [Cited by in F6Publishing: 155] [Article Influence: 14.5] [Reference Citation Analysis]
47 Ho M, Leu SJ, Sun G, Tao M, Tang S, Sun K. IL-27 Directly Restrains Lung Tumorigenicity by Suppressing Cyclooxygenase-2-Mediated Activities. J Immunol 2009;183:6217-26. [DOI: 10.4049/jimmunol.0901272] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 4.5] [Reference Citation Analysis]
48 Liebhart J, Polak M, Dabrowski A, Dobek R, Liebhart E, Dor-Wojnarowska A, Barg W, Kulczak A, Medrala W, Gladysz U, Lange A. The G/G genotype of transforming growth factor beta 1 (TGF-beta1) single nucleotide (+915G/C) polymorphism coincident with other host and environmental factors is associated with irreversible bronchoconstriction in asthmatics. Int J Immunogenet 2008;35:417-22. [PMID: 19046298 DOI: 10.1111/j.1744-313X.2008.00771.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
49 Kavathia N, Jain A, Walston J, Beamer BA, Fedarko NS. Serum markers of apoptosis decrease with age and cancer stage. Aging (Albany NY) 2009;1:652-63. [PMID: 20157546 DOI: 10.18632/aging.100069] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
50 Koukourakis GV, Baksevanis CN, Zambatis H, Gritzapis A, Maltezos E, Simopoulos C, Koukourakis MI. Amifostine enhances recovery and expansion of peripheral FAS/CD95+ T- and NK-cell subpopulations during radiotherapy of patients with head-neck cancer. International Journal of Radiation Biology 2009;85:96-104. [DOI: 10.1080/09553000802635070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
51 Teicher BA. Acute and chronic in vivo therapeutic resistance. Biochemical Pharmacology 2009;77:1665-73. [DOI: 10.1016/j.bcp.2009.01.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
52 Liao W, Yu C, Lan CE, Lee C, Chang C, Chang LW, You H, Yu H. Differential effects of arsenic on cutaneous and systemic immunity: focusing on CD4+ cell apoptosis in patients with arsenic-induced Bowen's disease. Carcinogenesis 2009;30:1064-72. [DOI: 10.1093/carcin/bgp095] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
53 Hofmann G, Langsenlehner U, Langsenlehner T, Yazdani-Biuki B, Clar H, Gerger A, Fuerst F, Samonigg H, Krippl P, Renner W. A common hereditary single-nucleotide polymorphism in the gene of FAS and colorectal cancer survival. J Cell Mol Med 2009;13:3699-702. [PMID: 19298528 DOI: 10.1111/j.1582-4934.2009.00720.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
54 Tang SJ, Ho MY, Cho HC, Lin YC, Sun GH, Chi KH, Wang YS, Jhou RS, Yang W, Sun KH. Phosphoglycerate kinase 1-overexpressing lung cancer cells reduce cyclooxygenase 2 expression and promote anti-tumor immunity in vivo. Int J Cancer 2008;123:2840-8. [PMID: 18814280 DOI: 10.1002/ijc.23888] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
55 Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene 2008;27:5894-903. [DOI: 10.1038/onc.2008.268] [Cited by in Crossref: 127] [Cited by in F6Publishing: 117] [Article Influence: 9.1] [Reference Citation Analysis]
56 Kumar V, Becker T, Jansen S, van Barneveld A, Boztug K, Wölfl S, Tümmler B, Stanke F. Expression levels of FAS are regulated through an evolutionary conserved element in intron 2, which modulates cystic fibrosis disease severity. Genes Immun 2008;9:689-96. [PMID: 18685642 DOI: 10.1038/gene.2008.63] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
57 Ho MY, Sun GH, Leu SJ, Ka SM, Tang SJ, Sun KH. Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma. Int J Cancer 2008;123:123-33. [PMID: 18386791 DOI: 10.1002/ijc.23474] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
58 Han H, Xu L, Liu XS, Si HY, Wang BZ. Expression of transforming growth factor β1 and its type I receptor in gastric cancer. Shijie Huaren Xiaohua Zazhi 2008; 16(8): 856-861 [DOI: 10.11569/wcjd.v16.i8.856] [Reference Citation Analysis]
59 Wallach-Dayan SB, Golan-Gerstl R, Breuer R. Evasion of myofibroblasts from immune surveillance: a mechanism for tissue fibrosis. Proc Natl Acad Sci U S A 2007;104:20460-5. [PMID: 18077384 DOI: 10.1073/pnas.0705582104] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 3.1] [Reference Citation Analysis]
60 Sørensen MR, Thomsen AR. Virus-based immunotherapy of cancer: what do we know and where are we going? APMIS 2007;115:1177-93. [DOI: 10.1111/j.1600-0643.2007.00802.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
61 Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol. 2007;42:113-185. [PMID: 17562450 DOI: 10.1080/10409230701340019] [Cited by in Crossref: 263] [Cited by in F6Publishing: 244] [Article Influence: 17.5] [Reference Citation Analysis]
62 Ogino T, Moriai S, Ishida Y, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, Ferrone S. Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. Int J Cancer 2007;120:2401-10. [PMID: 17315195 DOI: 10.1002/ijc.22334] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
63 Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121:1-14. [PMID: 17386080 DOI: 10.1111/j.1365-2567.2007.02587.x] [Cited by in Crossref: 593] [Cited by in F6Publishing: 587] [Article Influence: 39.5] [Reference Citation Analysis]
64 Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121:1-14. [PMID: 17386080 DOI: 10.1111/j.1365-2567.2007.02587] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Mustafa T, Mogga SJ, Mfinanga SG, Mørkve O, Sviland L. Immunohistochemical analysis of cytokines and apoptosis in tuberculous lymphadenitis. Immunology 2006;117:454-62. [PMID: 16556259 DOI: 10.1111/j.1365-2567.2005.02318.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
66 Feng Y, Ariza ME, Goulet AC, Shi J, Nelson MA. Death-signal-induced relocalization of cyclin-dependent kinase 11 to mitochondria. Biochem J 2005;392:65-73. [PMID: 16004605 DOI: 10.1042/BJ20050195] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
67 Schmidt J, Patrut EM, Ma J, Jäger D, Knaebel HP, Büchler MW, Märten A. Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI). Cancer Immunol Immunother 2006;55:1396-405. [PMID: 16485127 DOI: 10.1007/s00262-006-0140-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
68 Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions Between Human Mesenchymal Stem Cells and Natural Killer Cells. Stem Cells 2006;24:74-85. [DOI: 10.1634/stemcells.2004-0359] [Cited by in Crossref: 623] [Cited by in F6Publishing: 605] [Article Influence: 38.9] [Reference Citation Analysis]
69 Zhu Q, Liu JY, Xu HW, Yang CM, Zhang AZ, Cui Y, Wang HB. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system. World J Gastroenterol 2005; 11(39): 6125-6129 [PMID: 16273638 DOI: 10.3748/wjg.v11.i39.6125] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
70 Lemasters JJ. Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis. Gastroenterology. 2005;129:351-360. [PMID: 16012960 DOI: 10.1053/j.gastro.2005.06.006] [Cited by in Crossref: 99] [Cited by in F6Publishing: 83] [Article Influence: 5.8] [Reference Citation Analysis]
71 Enarsson K, Johnsson E, Lindholm C, Lundgren A, Pan-Hammarström Q, Strömberg E, Bergin P, Baunge EL, Svennerholm AM, Quiding-Järbrink M. Differential mechanisms for T lymphocyte recruitment in normal and neoplastic human gastric mucosa. Clin Immunol. 2006;118:24-34. [PMID: 16157508 DOI: 10.1016/j.clim.2005.08.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
72 Xu T, Sun BC, Li Q, Hao XS. Role of cytokines in promoting immune escape of FasL-expressing human colon cancer cells. World J Gastroenterol 2005; 11(25): 3915-3919 [PMID: 15991293 DOI: 10.3748/wjg.v11.i25.3915] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
73 Zhang C, Zhang J, Wei H, Tian Z. Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity? Int Immunopharmacol 2005;5:1099-111. [PMID: 15914316 DOI: 10.1016/j.intimp.2005.03.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
74 Peter ME, Legembre P, Barnhart BC. Does CD95 have tumor promoting activities? Biochim Biophys Acta 2005;1755:25-36. [PMID: 15907590 DOI: 10.1016/j.bbcan.2005.01.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 37] [Article Influence: 0.8] [Reference Citation Analysis]
75 Stoicov C, Saffari R, Cai X, Hasyagar C, Houghton J. Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling. Gene. 2004;341:1-17. [PMID: 15474284 DOI: 10.1016/j.gene.2004.07.023] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 3.8] [Reference Citation Analysis]
76 Xu T, Li Q, Hao XS. Relationship between expression of functional Fas ligand in human colon cancer cells and tumor's immune escape. Shijie Huaren Xiaohua Zazhi 2004; 12(9): 2066-2069 [DOI: 10.11569/wcjd.v12.i9.2066] [Reference Citation Analysis]